IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

CUBIST PHARMACEUTICALS LLC,	)	
	)	
Plaintiff,	)	
	)	
v.	)	C.A. No. _____
	)	
DR. REDDY'S LABORATORIES, LTD. and DR. REDDY'S LABORATORIES, INC.,	)	
	)	
Defendants.	)	

COMPLAINT

Plaintiff Cubist Pharmaceuticals LLC, by its attorneys, alleges as follows:

NATURE OF THE ACTION

1. This is an action for patent infringement under the patent laws of the United States, Title 35, United States Code, that arises out of the filing by Dr. Reddy's Laboratories, Ltd. ("DRL Ltd.") and Dr. Reddy's Laboratories, Inc. ("DRL Inc.") (collectively, "DRL" or "Defendants") of Abbreviated New Drug Application ("ANDA") No. 208375 with the U.S. Food and Drug Administration ("FDA") seeking approval to manufacture and sell a generic version of CUBICIN® prior to the expiration of U.S. Patent Nos. 6,468,967; 6,852,689; 8,058,238; and 8,129,342.

PARTIES

2. Plaintiff Cubist Pharmaceuticals LLC ("Cubist" or "Plaintiff") is a company organized and existing under the laws of the State of Delaware, with its principal place of business at 65 Hayden Avenue, Lexington, Massachusetts.

3. Upon information and belief, Defendant DRL Ltd. is a corporation organized and existing under the laws of India, with its principal place of business at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India. Upon information and belief, DRL Ltd.,

itself and through its subsidiaries and agents, including DRL Inc., manufactures, distributes and/or imports generic drugs for sale and use throughout the United States, including in this judicial district.

4. Upon information and belief, Defendant DRL Inc. is a corporation organized and existing under the laws of New Jersey, with its registered office at 107 College Road East, Princeton, NJ 08540. Upon information and belief, DRL Inc. manufactures and/or distributes generic drugs for sale and use throughout the United States and in this judicial district at the direction, under the control, and for the direct benefit of DRL Ltd.

5. Upon information and belief, DRL Ltd. and DRL Inc. acted collaboratively in the preparation and submission of ANDA No. 208375. Upon information and belief, DRL's preparation and submission of ANDA No. 208375 was done at the direction, under the control, and for the direct benefit of DRL Ltd.

6. Upon information and belief, following any FDA approval of ANDA No. 208375, DRL Ltd., itself and through its subsidiaries and agents, including DRL Inc., will make, use, offer to sell, and/or sell the generic products that are the subject of ANDA No. 208375 throughout the United States, including in the State of Delaware, and/or import such generic products into the United States.

JURISDICTION AND VENUE

7. This action arises under the patent laws of the United States of America and this Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

8. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400(b).

9. The court has personal jurisdiction over each of the Defendants because, among other things, they have each committed, or aided, abetted, contributed to and/or participated in

the commission of, a tortious act of patent infringement that has led to foreseeable harm and injury to Cubist, a Delaware corporation, which sells CUBICIN® throughout the United States, including the State of Delaware. This Court also has personal jurisdiction over the Defendants by virtue of, among other things, their systematic and continuous contacts with Delaware as set forth below, and for other reasons that will be presented to the Court if jurisdiction is challenged.

10. Upon information and belief, DRL Ltd., itself and through its subsidiaries and agents, including DRL Inc., currently manufactures and distributes for sale dozens of drug products throughout the United States, including in this judicial district.

11. Upon information and belief, DRL Ltd. directs the operations, management and activities of DRL Inc. in the United States.

12. Upon information and belief, DRL Ltd., directly or through DRL Inc., routinely files ANDAs seeking FDA approval to market its drug products in the United States.

13. Upon information and belief, DRL Ltd. and DRL Inc. collaborate in the manufacture, marketing, and sale of many pharmaceutical products (including generic drug products manufactured and sold pursuant to approved ANDAs) throughout the United States, including in this judicial district.

14. Upon information and belief, DRL Inc. sells generic drug products in the United States, including in this judicial district, that are manufactured by DRL Ltd.

15. DRL has taken advantage of the jurisdiction of this Court by affirmatively filing counterclaims and requesting entry of judgment in other actions before this Court, including *Teva Pharmaceuticals USA, Inc. et al. v. Dr. Reddy's Laboratories, Ltd., et al.*, No. 15-cv-306-GMS (D. Del.); *Cephalon, Inc. v. Dr. Reddy's Laboratories, Ltd. et al.*, No. 15-cv-179 (GMS)

(D. Del.); and *Allos Therapeutics, Inc. et al. v. Teva Pharmaceuticals USA, Inc. et al.*, No. 14-778-RGA (D. Del.).

16. This Court has personal jurisdiction over DRL Inc. by virtue of, among other things, its systematic and continuous contacts with Delaware.

17. This Court has personal jurisdiction over DRL Ltd. by virtue of, among other things, its systematic and continuous contacts with Delaware.

18. In the alternative, this Court may exercise personal jurisdiction over DRL Ltd. pursuant to Federal Rule of Civil Procedure 4(k)(2) because (a) Plaintiffs' claims arise under federal law; (b) DRL Ltd. is a foreign company not subject to personal jurisdiction in the courts of any state; and (c) DRL Ltd. has sufficient contacts with the United States as a whole, including but not limited to marketing and/or selling generic pharmaceutical products that are distributed and sold throughout the United States, such that this Court's exercise of jurisdiction over DRL Ltd. satisfies due process.

BACKGROUND

19. CUBICIN® (daptomycin for injection) is an intravenous bactericidal antibiotic approved by the FDA for the treatment of complicated skin and skin structure infections caused by certain Gram-positive microorganisms, such as *Staphylococcus aureus*, including methicillin-resistant strains, also known as MRSA. CUBICIN® is also approved for the treatment of *S. aureus* bloodstream infections (bacteremia), including right-sided infective endocarditis caused by MRSA.

20. Cubist sells CUBICIN® in the United States pursuant to a New Drug Application that has been approved by the FDA.

21. United States Patent No. 6,468,967 ("the '967 patent"), entitled "Methods for Administration of Antibiotics" (Exhibit A hereto), was duly and legally issued on October 22, 2002. The '967 patent, which is owned by Cubist, will expire on September 24, 2019.

22. United States Patent No. 6,852,689 ("the '689 patent"), entitled "Methods for Administration of Antibiotics" (Exhibit B hereto), was duly and legally issued on February 8, 2005. The '689 patent, which is owned by Cubist, will expire on September 24, 2019.

23. United States Patent No. 8,058,238 ("the '238 patent"), entitled "High Purity Lipopeptides" (Exhibit C hereto), was duly and legally issued on November 15, 2011. The '238 patent, which is owned by Cubist, will expire on November 28, 2020.

24. United States Patent No. 8,129,342 ("the '342 patent"), entitled "High Purity Lipopeptides" (Exhibit D hereto), was duly and legally issued on March 6, 2012. The '342 patent, which is owned by Cubist, will expire on November 28, 2020.

25. CUBICIN®, or its use, is covered by one or more claims of the '967, '689, '238, and '342 patents, which have been listed in connection with CUBICIN® in the FDA's publication, *Approved Drug Products with Therapeutic Equivalence Evaluations*, referred to as the "Orange Book."

26. By letter dated December 9, 2015 (the "Notice Letter"), DRL notified Cubist that it had submitted to the FDA ANDA No. 208375 for daptomycin for injection, for intravenous use, a generic version of CUBICIN® ("DRL's ANDA Product").

27. In the Notice Letter, DRL stated that its ANDA included certifications pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) with respect to the '967, '689, '238, and '342 patents and alleged that the '967, '689, '238, and '342 patents are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, offer for sale, or sale of DRL's ANDA Product.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.